Author

M Kabba

Observed name: Mariatu Kabba

Observed institutions: University of Sierra Leone, London School of Hygiene & Tropical Medicine, Mwanza Intervention Trials Unit, National Institute for Medical Research

OpenAlex ID: A5066526206

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

2021 · Muhammed O Afolabi, David Ishola, et al. · The Lancet Infectious Diseases · 94

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

2021 · David Ishola, Daniela Manno, et al. · The Lancet Infectious Diseases · 93

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

2023 · Edward Man-Lik Choi, Boris Lacarra, et al. · The Lancet Global Health · 18

Making sense of girls empowerment in Sierra Leone: a conversation

2021 · Aisha Fofana Ibrahim, Alice James, et al. · International Politics Reviews · 8

Works count: 4

Citation count: 213

H-index: 4

I10-index: 3